NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$25.53 +0.59 (+2.37 %)
(As of 01/16/2019 04:00 PM ET)
Previous Close$24.94
Today's Range$24.86 - $26.10
52-Week Range$14.81 - $55.48
Volume1.63 million shs
Average Volume2.37 million shs
Market Capitalization$1.61 billion
P/E Ratio-5.31
Dividend YieldN/A
Beta1.89
Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor candidate for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Current Ratio6.61
Quick Ratio6.51

Price-To-Earnings

Sales & Book Value

Annual Sales$22.55 million
Price / Sales75.21
Price / Cash FlowN/A
Book Value$5.36 per share
Price / Book4.76

Profitability

Net Income$-286,090,000.00
Net Margins-1,020.52%
Return on Assets-69.69%

Miscellaneous

Employees252
Market Cap$1.61 billion
OptionableOptionable

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) issued its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating analysts' consensus estimates of ($1.54) by $0.46. The biopharmaceutical company had revenue of $14.20 million for the quarter, compared to analysts' expectations of $7.10 million. Portola Pharmaceuticals had a negative net margin of 1,020.52% and a negative return on equity of 135.08%. The company's revenue was up 270.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.41) earnings per share. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

6 equities research analysts have issued twelve-month price targets for Portola Pharmaceuticals' shares. Their forecasts range from $30.00 to $50.00. On average, they anticipate Portola Pharmaceuticals' share price to reach $35.50 in the next twelve months. This suggests a possible upside of 39.1% from the stock's current price. View Analyst Price Targets for Portola Pharmaceuticals.

What is the consensus analysts' recommendation for Portola Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Portola Pharmaceuticals.

What are Wall Street analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (1/10/2019)
  • 2. Cowen Inc analysts commented, "Rhythm reported 2Q18 financial results yesterday and we spoke w/ mgmt for an update. As a reminder, the company completed enrollment of both setmelanotide Phase 3 trials in POMC and LepR Deficiency patients in Jun 2018. Mgmt reiterated guidance for results from these trials in 3Q19. We expect positive outcomes based on Phase 2 data. Encouraging long-term Phase 2 data in Bardet-Biedl (BBS) and initial Phase 2 data in Alstrom, POMC Heterozygous, and POMC Epigenetic were announced earlier this year and mgmt reiterated plans to start a single Phase 3 trial w/ both Bardet-Biedl and Alstrom patients in 2H18. Demonstration of consistent impact on appetite and weight across several genetic obesity diseases in 2Q18 has increased our conviction. BUY." (8/9/2018)

Has Portola Pharmaceuticals been receiving favorable news coverage?

Headlines about PTLA stock have trended somewhat negative recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 54)
  • Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 66)
  • Dr. John H. Lawrence III, Sr. VP & Chief Medical Officer (Age 60)
  • Mr. Tao Fu, Consultant (Age 46)
  • Mr. J. Scott Garland, Pres & CEO (Age 49)

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $25.53.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $1.61 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.

What is Portola Pharmaceuticals' official website?

The official website for Portola Pharmaceuticals is http://www.portola.com.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  409 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  667
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel